Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean category antidepressive agent and group approved?
Displaying drugs 401 - 425 of 10409 in total

Buclizine

Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects , belonging to the piperazine derivative family of drugs. It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. Following this, it was touted to be effective as an appetite stimulant in children when administered...
Approved
Matched Description: … It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. ... Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects [L6220], belonging ... [L6217] Following this, it was touted to be effective as an appetite stimulant in children when administered …
Matched Categories: … Histamine Agents ... Anticholinergic Agents ... Agents producing tachycardia ... QTc Prolonging Agents ... Neurotransmitter Agents …

Lactitol

Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from lactose. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. sucrose). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides...
Approved
Investigational
Matched Description: … [A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in ... [A190912] Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other …
Matched Categories: … Flavoring Agents ... Sweetening Agents ... Gastrointestinal Agents …

Hydroxocobalamin

Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency. It is also used in cyanide poisoning, Leber's optic atrophy, and toxic amblyopia.
Approved
Matched Description: … Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B …
Matched Categories: … Hematologic Agents …

Tyropanoic acid

Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image .
Approved

Aripiprazole lauroxil

Aripiprazole lauroxil is a long-acting injectable atypical antipsychotic drug used in the treatment of schizophrenia in adult patients. It is a prodrug of aripiprazole, which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors . Affecting about 1% of the...
Approved
Investigational
Matched Description: … a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an ... D2 receptors have been the most common target for antipsychotic agents used in the treatment of schizophrenia ... Aripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada …
Matched Categories: … Antidepressive Agents ... Antipsychotic Agents ... Serotonin Agents ... Neurotoxic agents ... Tranquilizing Agents …

Cetuximab

Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible...
Approved
Matched Description: … [A227963] Approved by the FDA in February 2004 under the brand name ERBITUX, cetuximab is used for ... infusion and is used as monotherapy or in combination with other chemotherapies, including platinum agents …
Matched Categories: … Antineoplastic Agents ... Antineoplastic Agents, Immunological ... Antineoplastic and Immunomodulating Agents …

Colchicine

Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events....
Approved
Matched Description: … [A183611] Its use was first approved by the FDA in 1961. ... Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum …
Matched Categories: … Antimitotic Agents ... Agents Causing Muscle Toxicity …

Ezogabine

Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy....
Approved
Investigational
Matched Description: … FDA approved in June 10, 2011 under the name of ezogabine. ... developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an …
Matched Categories: … QTc Prolonging Agents ... Central Nervous System Agents ... Potential QTc-Prolonging Agents …

Chikungunya vaccine (live, attenuated)

Chikungunya virus (CHIKV) is a member of the Alphavirus genus that was first identified in Tanzania in 1952. It is spread primarily by the bite of infected mosquitos of the Aedes genus. Infection with CHIKV causes chikungunya fever, an illness characterized by acute fever and severe, persistent arthralgia. Prior to...
Approved
Matched Description: … Infection with CHIKV causes chikungunya fever, an illness characterized by acute fever and severe, persistent ... [L48786] There are no approved treatments for active chikungunya virus infection. ... [L48731] Chikungunya vaccine (live, attenuated) - marketed under the name Ixchiq - was approved by …

Recombinant stabilized RSV B prefusion F antigen

Recombinant stabilized RSV B prefusion F antigen is one component of a bivalent respiratory syncytial virus (RSV) vaccine called Abrysvo. The vaccine comprises two antigens - the other being recombinant stabilized RSV A prefusion F antigen - which have been expressed in Chinese hamster ovary cell lines and then purified...
Approved
Matched Description: … is reconstituted with sterile water prior to injection and does not require the co-administration of an ... [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in ... [L49560] It is the first RSV vaccine approved for use in pregnant patients to prevent RSV in infants. …

Adalimumab

Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced...
Approved
Experimental
Matched Description: … - which was approved in August 2022 -,[L42935] and adalimumab-aacf - which was approved in October 2023 ... [L44953] Adalimumab-adaz was approved by the FDA on October 31, 2018. ... Adalimumab-atto was the first adalimumab biosimilar approved by the FDA in 2016. …
Matched Categories: … Antirheumatic Agents ... Anti-Inflammatory Agents ... Agents reducing cytokine levels ... Immunosuppressive Agents ... Disease-modifying Antirheumatic Agents …

Tovorafenib

Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation,...
Approved
Investigational

Moxidectin

Moxidectin is a potent, broad-spectrum endectocide (antiparasitic that is active against endo- and ecto-parasites) with activity against nematodes, insects, and acari. It was first used in cattle followed by an approved use in general animals. It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of...
Approved
Investigational
Vet approved
Matched Description: … It was first used in cattle followed by an approved use in general animals. ... [A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June …
Matched Categories: … Antinematodal Agents ... Anti-Infective Agents ... Antiparasitic Agents …

Plasminogen

Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as fibrinolysin - as part of the fibrinolytic pathway that breaks down fibrin blood clots. This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond...
Approved
Matched Description: … to form on the mucous membranes of patients, providing an unmet medical need for patients with this ... [L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh ... [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions …
Matched Categories: … Hematologic Agents ... Fibrinolytic Agents ... Cardiovascular Agents ... Fibrin Modulating Agents …

Asparaginase Erwinia chrysanthemi

Asparaginase Erwinia chrysanthemi is an asparaginase-specific enzyme derived from Erwinia chrysanthemi used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in...
Approved
Investigational
Matched Description: … _ used as an anticancer agent. ... [L149] In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the ... [A236359] Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat …
Matched Categories: … Antineoplastic Agents ... Hepatotoxic Agents …

Macimorelin

Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels...
Approved
Investigational
Matched Description: … More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an ... Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential ... Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market …
Matched Categories: … Diagnostic Agents ... QTc Prolonging Agents ... Highest Risk QTc-Prolonging Agents …

Cefditoren

Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
Approved
Investigational
Matched Description: … Cefditoren is an oral third-generation cephalosporin. …
Matched Categories: … Anti-Bacterial Agents ... Anti-Infective Agents ... Nephrotoxic agents …

Potassium citrate

Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent. Potassium citrate is used to treat...
Approved
Investigational
Vet approved
Matched Categories: … Natriuretic Agents ... Agents causing hyperkalemia ... Respiratory System Agents …

Dacomitinib

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone ... [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. …
Matched Categories: … Antineoplastic Agents ... Antineoplastic and Immunomodulating Agents …

Sibutramine

Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the...
Approved
Illicit
Investigational
Withdrawn
Matched Description: … USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an …
Matched Categories: … Antidepressive Agents ... Anti-Obesity Agents ... Serotonin Agents ... Agents producing tachycardia ... Central Nervous System Agents …

Rabies virus inactivated antigen, A

Rabies virus inactivated antigen, A is an inactivated virus vacine for the intramuscular injection. It is an active immunization against rabies that can be administered pre- or post-exposure to the rabies virus.
Approved
Investigational
Matched Description: … Rabies virus inactivated antigen, A is an inactivated virus vacine for the intramuscular injection. ... It is an active immunization against rabies that can be administered pre- or post-exposure to the rabies …

Daridorexant

Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Description: … Daridorexant was designed via an intensive drug discovery program to improve the potency and maximize ... attention after discovering the role of orexin signalling pathway in wakefulness and [almorexant], an ... [A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ. …
Matched Categories: … Wakefulness-Promoting Agents …

Rimegepant

Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. ... [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine ... approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved …

Nabumetone

Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree...
Approved
Matched Categories: … Nephrotoxic agents ... Agents causing hyperkalemia ... Antirheumatic Agents ... Anti-Inflammatory Agents ... Photosensitizing Agents …

Nevirapine

A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Approved
Matched Categories: … Anti-HIV Agents ... Antiviral Agents ... Anti-Infective Agents ... Anti-Retroviral Agents ... Hepatotoxic Agents …
Displaying drugs 401 - 425 of 10409 in total